The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

ABSTRACT Introduction: Proton Pump inhibitors (PPIs) are commonly used for a variety of
acid related disorders. Despite the overall effectiveness and safety profile of PPIs, some …

Objective: We extend the literature on comorbidity measurement by developing 2 indices,
based on the Elixhauser Comorbidity measures, designed to predict 2 frequently reported …

The current manuscript is an update of the original Practical Guide, published in June 2013
[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart …

New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to
prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and …

Background The burden of daily basal insulins often causes hesitancy and delays in the
initiation of insulin therapy. Basal insulin Fc (BIF, insulin efsitora alfa), designed for once …

Objectives To assess the impact of reduced frequency of oral therapies from multiple-dosing
schedules to a once-daily (OD) dosing schedule on adherence, compliance, persistence …

The benefit of once-weekly basal insulin is less frequent dosing, which has the potential to
reduce the barrier to injection therapy and impact patient activation, adherence and …

Despite significant advances in health care over the last 50 years, the global cardiovascular
disease burden continues to increase with dire im‐plications. It is well known that …

Background Novel oral anticoagulants are approved in several indications: rivaroxaban,
apixaban, and dabigatran for the prevention of venous thromboembolism after elective hip …